Gewinn- und Verlustrechnung von AptarGroup, Inc.

Aurora Investment Counsel acquired a new stake in shares of AptarGroup, Inc. (NYSE: ATR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 11,785 shares of the industrial products company's stock, valued at approximately $1,475,000. Other hedge funds have

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress including FDA clearance of its Investigational New Drug (IND) application for ATR 1072 and continued achievements under its collaboration with Bristol Myers Squibb (BMS). "Our team continues to execute well, achieving FDA clearance of our IND for ATR 1072 and launching Corventis — Atrium's first Phase 1/2 trial and the first clinical study to evaluate a potential disease-modifying treatment for people living with PRKAG2 syndrome," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics.

Bank of America Corp DE boosted its position in AptarGroup, Inc. (NYSE: ATR) by 7.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 485,718 shares of the industrial products company's stock after buying an additional 32,420 shares during the

ATR tops Q2 earnings and revenue estimates as pharma and beverage growth lift quarterly revenues above $1B for the first time despite margin pressure.

California State Teachers Retirement System grew its position in shares of AptarGroup, Inc. (NYSE: ATR) by 24.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 77,227 shares of the industrial products company's stock after buying an additional 15,158

AptarGroup, Inc. (NYSE: ATR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month

Review AptarGroup's (ATR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

AptarGroup, Inc. (ATR) Q2 2026 Earnings Call Transcript

AptarGroup NYSE: ATR reported second-quarter sales growth across each of its three segments and adjusted earnings per share above its guidance range, supported by stronger-than-expected performance in its Pharma business. The company also said President and CEO Stephan Tanda will retire later this year, with President and CEO Designate Gael Touya set to assume the CEO role on Sept.